Bristol Myers Squibb Company (BMY) vs Novartis AG (NVS)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Novartis AG NVS 150.62 +0.16%
Bristol Myers Squibb Company and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $275.3B against $123.7B — 2.2× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.2× against 22.6×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against 2.73%. Novartis AG has the higher net margin (22.5% vs 18.9%) and the lower return on invested capital (13.1% vs 13.7%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.22% vs 3.15%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 14 and Novartis AG on 9.
Valuation
Profitability
| Metric | BMY | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 74.74% | 72.77% |
| Operating margin | 24.22% | 30.17% | 18.77% |
| Net margin | 18.87% | 22.50% | 8.27% |
| Free cash flow margin | 23.26% | 26.77% | 17.18% |
| Return on equity | 46.63% | 30.37% | 5.87% |
| Return on assets | 10.18% | 11.27% | 2.57% |
| Return on invested capital | 13.69% | 13.14% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack